zopiclone has been researched along with lamotrigine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Feldmann, J; Jurcsik, A; Kopcsányi, H; Péch, Z | 1 |
| Krocker, K; Sautter, J; Tattoli, L; Tsokos, M | 1 |
6 other study(ies) available for zopiclone and lamotrigine
| Article | Year |
|---|---|
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
[Difficulties in detecting the causative agent of an adverse drug reaction in a complicated case].
Topics: Administration, Cutaneous; Administration, Oral; Anticonvulsants; Antidepressive Agents; Atorvastatin; Azabicyclo Compounds; Drug Eruptions; Female; Heptanoic Acids; Humans; Lamotrigine; Middle Aged; Piperazines; Pyrroles; Risperidone; Sertraline; Skin Tests; Triazines | 2008 |
Multidrug-related leukocytoclastic vasculitis raising suspicion of sexual homicide-things are not always what they seem.
Topics: Adult; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Azabicyclo Compounds; Benzhydryl Compounds; Calcium Channel Blockers; Desvenlafaxine Succinate; Diphenhydramine; Female; Forensic Pathology; Hemorrhage; Humans; Hypnotics and Sedatives; Lamotrigine; Modafinil; Piperazines; Pregabalin; Pyridines; Subcutaneous Tissue; Tramadol; Triazines; Vasculitis, Leukocytoclastic, Cutaneous; Wakefulness-Promoting Agents; Zolpidem | 2016 |